Search | Clinical Trials Finder

Conditions: Alcohol Use Disorder, Alcoholic Liver Disease, Microbiome
Interventions: VSL #3 112.5 Capsule, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pediatric Brain Tumor
Interventions: Ketogenic diet, BCNU; Procedure · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cardiac Rehabilitation, Heart Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hyperuricemia
Interventions: low-fructose diet, Allopurinol; Other · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 40 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 28
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 21 more

Conditions: Erectile Dysfunction
Interventions: delivery system; Other
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Pre-diabetes, Diabetes
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 30 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Bridgeport, Connecticut • New Haven, Connecticut

Conditions: Longitudinal Studies, Prospective Studies, Biomarkers, Predictive Value of Tests, Telemedicine, Time of Death, Time Perception, Time Reaction, Time Efficiency, Time Management, Population, Population Groups, Epidemic Disease, Pandemic, Sex Behavior, Sex Characteristics, Sex Hormone, Cardio-pulmonary, Surgical, Drugs of Abuse, Health Risks, Clinical Outcomes
Interventions: No Study-Assigned Intervention; Other
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2076
U.S. locations: 1
States / cities: New York, New York

Conditions: Nicotine Addiction, E-Cig Use, Cigarette Smoking, Sex Differences
Interventions: E-liquid Flavor 1, E-liquid Flavor 2, E-liquid Flavor 3; Other
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 44 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alcohol Use Disorder
Interventions: Naltrexone; Drug
Lead sponsor: Milky Kohno; Other
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Congenital Adrenal Hyperplasia
Interventions: Questionnaires/Interviews; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 10 Years to 13 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Alcohol-Related Disorders, Substance-Related Disorders
Interventions: The Women's Recovery Group, mixed-gender Group Drug Counseling; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Stroke
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 45 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV Infections, Staphylococcal Infections
Interventions: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 4
States / cities: San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more

Conditions: Metastatic Cancer
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nicotine
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy, Hyperinsulinemic Hypoglycemia, Familial 1, Diabetes Mellitus, Adrenoleukodystrophy, Neonatal, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Beta-ketothiolase Deficiency, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Primary Hyperoxaluria Type 1, Congenital Bile Acid Synthesis Defect Type 2, Pyridoxine-Dependent Epilepsy, Hereditary Fructose Intolerance, Hypophosphatasia, Hyperargininemia, Mucopolysaccharidosis Type 6, Argininosuccinic Aciduria, Citrullinemia, Type I, Wilson Disease, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Biotinidase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Intrinsic Factor Deficiency, Usher Syndrome Type 1D/F Digenic (Diagnosis), Cystic Fibrosis, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Cystinosis, Chronic Granulomatous Disease, Cerebrotendinous Xanthomatoses, Maple Syrup Urine Disease, Type 2, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Thyroid Dyshormonogenesis 6, Thyroid Dyshormonogenesis 5, Supravalvar Aortic Stenosis, Factor X Deficiency, Hemophilia A, Hemophilia B, Tyrosinemia, Type I, Fructose 1,6 Bisphosphatase Deficiency, Glycogen Storage Disease Type I, G6PD Deficiency, Glycogen Storage Disease II, Galactokinase Deficiency, Mucopolysaccharidosis Type IV A, Galactosemias, Guanidinoacetate Methyltransferase Deficiency, Agat Deficiency, Glutaryl-CoA Dehydrogenase Deficiency, Gtp Cyclohydrolase I Deficiency, Hyperinsulinism-Hyperammonemia Syndrome, Primary Hyperoxaluria Type 2, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Mitochondrial Trifunctional Protein Deficiency, Sickle Cell Disease, Beta-Thalassemia, Holocarboxylase Synthetase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, Primary Hyperoxaluria Type 3, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Apparent Mineralocorticoid Excess, HSDB, CBAS1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 1, Severe Combined Immunodeficiency, X Linked, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Diabetes Mellitus, Permanent Neonatal, Isovaleric Acidemia, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Jervell and Lange-Nielsen Syndrome 2, Hyperinsulinemic Hypoglycemia, Familial, 2, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Jervell and Lange-Nielsen Syndrome 1, Lysosomal Acid Lipase Deficiency, CblF, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, Waardenburg Syndrome Type 2A, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Methylmalonic Aciduria and Homocystinuria Type cblC, MAHCD, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Congenital Disorder of Glycosylation Type 1B, Mthfr Deficiency, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Usher Syndrome, Type 1B, N-acetylglutamate Synthase Deficiency, Ornithine Transcarbamylase Deficiency, Phenylketonurias, Waardenburg Syndrome Type 1, Congenital Hypothyroidism, Propionic Acidemia, Usher Syndrome, Type 1F, Pancreatic Agenesis 1, Hereditary Hypophosphatemic Rickets, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, MOWS, Epilepsy, Early-Onset, Vitamin B6-Dependent, Pyridoxal Phosphate-Responsive Seizures, Pituitary Hormone Deficiency, Combined, 1, Ptsd, Dihydropteridine Reductase Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Retinoblastoma, Multiple Endocrine Neoplasia Type 2B, Pseudohypoaldosteronism, Type I, Liddle Syndrome, Biotin-Responsive Basal Ganglia Disease, SCD, DIAR1, GSD1C, Acrodermatitis Enteropathica, Thyroid Dyshormonogenesis 1, Riboflavin Transporter Deficiency, Waardenburg Syndrome, Type 2E, SRD, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Barth Syndrome, Adrenocorticotropic Hormone Deficiency, Transcobalamin II Deficiency, Thyroid Dyshormonogenesis 3, Segawa Syndrome, Autosomal Recessive, Autosomal Recessive Nonsyndromic Hearing Loss, Thyroid Dyshormonogenesis 2A, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Hypothyroidism Due to TSH Receptor Mutations, Usher Syndrome Type 1C, Usher Syndrome Type 1G (Diagnosis), Von Willebrand Disease, Type 3, Combined Immunodeficiency Due to ZAP70 Deficiency, Adenine Phosphoribosyltransferase Deficiency, Metachromatic Leukodystrophy, Canavan Disease, Menkes Disease, Carbonic Anhydrase VA Deficiency, Developmental and Epileptic Encephalopathy 2, 17 Alpha-Hydroxylase Deficiency, Smith-Lemli-Opitz Syndrome, Krabbe Disease, Glutathione Synthetase Deficiency, Mucopolysaccharidosis Type 7, Rett Syndrome, Molybdenum Cofactor Deficiency, Type A, Niemann-Pick Disease, Type C1, Niemann-Pick Disease Type C2, Ornithine Aminotransferase Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Leber Congenital Amaurosis 2, Dravet Syndrome, Mucopolysaccharidosis Type 3 A, Ornithine Translocase Deficiency, Carnitine-acylcarnitine Translocase Deficiency, Glucose Transporter Type 1 Deficiency Syndrome, Creatine Transporter Deficiency, Niemann-Pick Disease Type A, Pitt Hopkins Syndrome, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Ataxia With Isolated Vitamin E Deficiency, Angelman Syndrome, Prader-Willi Syndrome, Homocystinuria, Permanent Neonatal Diabetes Mellitus, Transient Neonatal Diabetes Mellitus, Factor VII Deficiency, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Glycogen Storage Disease IC, Glycogen Storage Disease Type IB, Central Hypoventilation Syndrome With or Without Hirschsprung Disease
Interventions: Confirmatory Testing; Diagnostic Test
Lead sponsor: RTI International; Other
Eligibility: 1 Day to 31 Days
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Generalized Anxiety Disorder
Interventions: Mindfulness Based Stress Reduction MBSR Intervention, Stress Education Control Condition (SE); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Marijuana Dependence
Interventions: Cognitive stressor; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV Infections
Interventions: Raltegravir + Truvada; Drug
Lead sponsor: David A Wohl, MD; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Circadian Misalignment, Sex Differences
Interventions: Day shift, Night shift; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Fatigue Syndrome
Interventions: Exercise test; Behavioral
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 3
States / cities: San Diego, California • Aurora, Colorado • Indianapolis, Indiana

Conditions: Seasonal Affective Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Alcoholic Liver Disease and the Gut Microbiome

Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis

Sex Differences in Barriers and Participation in Physical Activity During and Following Cardiac Rehabilitation

Gender Differences in the Metabolic Effects of Uric Acid

Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women

Caverject User Study

Gender Differences in Prevalence of Undiagnosed Diabetes in ACS

Clinical Time and Temporal Dynamics Study (CLIN-TIME)

Sex Differences in E-cig Perception: Study 1

Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use Disorder

Tweens to Teens Project at Penn State

The Women's Recovery Group Study: Stage I Trial

Sex Differences in Vascular Markers of Stroke Risk

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

Goals of Care Discussions for Hospitalized Patients With Advanced Cancer

Nicotine and Brain Imaging Research Study

Early Check: Expanded Screening in Newborns

MBSR Mechanisms in GAD

Sex Differences in Attentional Bias in Marijuana-dependent Individuals

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Does Circadian Misalignment Have Sex-Specific Effects on Metabolism?

Exercise-related Post-exertional Malaise

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Effects of Season on Melatonin Secretion in Healthy Men and Women and Patients With Seasonal Affective Disorder